Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094804 | 0.82 | ADORA1 (0.39) | ADORA1ADORA2AADORA2B | |
| SCHEMBL6093533 | 0.79 | ADORA1 (0.39) | ADORA1ADORA2AADORA2B | |
| SCHEMBL5229248 | 0.78 | ADORA1 (0.59) | ADORA1CYP1A2ADORA3ADORA2AADORA2B | |
| SCHEMBL6093117 | 0.74 | PDE2A (0.44) | ADORA1ADORA2AADORA2B | |
| SCHEMBL6095274 | 0.71 | ADORA1 (0.44) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL6093414 | 0.71 | ADORA1 (0.61) | ADORA1CYP1A2ADORA3ADORA2AADORA2B | |
| SCHEMBL5227169 | 0.71 | ADORA1 (0.65) | ADORA1CYP1A2ADORA3ADORA2AADORA2B | |
| SCHEMBL8127160 | 0.71 | ADORA2A (0.67) | ADORA2AADORA2B | |
| SCHEMBL5226847 | 0.70 | ADORA2B (0.39) | ADORA1ALDH1A1CYP1A2CYP2C19ADORA3 | |
| SCHEMBL5230505 | 0.69 | ADORA2B (0.66) | ADORA1ALDH1A1CYP1A2CYP2C19ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005430-B2 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| EP-1251130-B1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20030176698-A1 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1251130-A1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176698-A1 | Fused purine derivatives | PNP, NSUN2, CYP2W1 | ADORA1 64/4885ALDH1A1 2392/4885CYP1A2 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.